Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Drugs and Therapy
Published in: Cardiovascular Drugs and Therapy 6/2011

01-12-2011 | Editorial

The MAGIC Study and the Gastrointestinal Effects of Low-Dose Aspirin

Editorial to: “Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study” by H. Origasa et al.

Authors: John McNeil, Andrew Tonkin

Published in: Cardiovascular Drugs and Therapy | Issue 6/2011

Login to get access

Excerpt

In this edition of Cardiovascular Drugs and Therapy, Origasa and colleagues describe the rationale and design of the MAGIC Study, a large Japanese cohort study designed to assess the frequency of gastrointestinal complications associated with low-dose aspirin therapy [1]. Bleeding, particularly from the gastrointestinal tract is the most important adverse effect of aspirin but its frequency and consequences have not been well studied. In most large scale randomised trials the focus has been on the potential benefits with less rigorous assessment of the negative consequences of therapy. …
Literature
1.
Origasa H, Goto S, Shimada K, Uchiyama S, Okada Y, Sugano K, et al. Prospective cohort study of gastrointestinal complications and vascular diseases in patients taking aspirin: rationale and design of the MAGIC Study. Cardiovasc Drugs Ther. 2011;25: this issue.
2.
Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Therap. 1993;54:84–9.CrossRef
3.
Slattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin – analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 1995;37:509–11.PubMedCrossRef
4.
Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol. 2011;9:762–768.e6.PubMedCrossRef
5.
Fujisawa N, Inamori M, Endo H, Uchiyama T, Hosono K, Akiyama T, et al. Incidence of and risk factors for upper gastrointestinal complications in patients taking low-dose aspirin in Japan. Hepatogastroenterol. 2011;58:229–34.
6.
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–13.PubMedCrossRef
7.
Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011;124:621–9.PubMedCrossRef
8.
Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J. 2011;162:115–124 e2.PubMedCrossRef
9.
Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med. 2011;124:426–33.PubMedCrossRef
10.
Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60.PubMedCrossRef
11.
Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–83.PubMedCrossRef
12.
Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust. 2008;189:105–9.PubMed
Metadata
Title
The MAGIC Study and the Gastrointestinal Effects of Low-Dose Aspirin
Editorial to: “Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study” by H. Origasa et al.
Authors
John McNeil
Andrew Tonkin
Publication date
01-12-2011
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 6/2011
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-011-6345-1

Other articles of this Issue 6/2011

Cardiovascular Drugs and Therapy 6/2011 Go to the issue

Short Communication

C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding

OriginalPaper

Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome

ReviewPaper

Stroke Prevention in Atrial Fibrillation

OriginalPaper

Prospective Cohort Study of Gastrointestinal Complications and Vascular Diseases in Patients Taking Aspirin: Rationale and Design of the MAGIC Study

OriginalPaper

Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina

OriginalPaper

Abdominal Surgical Incision Induces Remote Preconditioning of Trauma (RPCT) via Activation of Bradykinin Receptors (BK2R) and the Cytochrome P450 Epoxygenase Pathway in Canine Hearts

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits